Patent US4865841A successfully refreshed from Google Patents.
US4865841A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and compositions for transient elimination of humoral immune antibodies
Assignee: Cypress Bioscience Inc
•
Filing: 1987-10-23
•
Granted: 1989-09-12
•
Expires: 2007-10-23
Abstract
Abstract Antibody is removed from the blood of patients who are being treated or diagnosed with exogenous macromolecules, such as immunotoxins. As the immunotoxins are foreign antigens, the patient will develop an immune response. The antibodies produced by the immune response upon subsequent immunization with the immunotoxins will interfere with the desired function of the immunotoxins by preventing them from binding with their specific target site. By extracorporeally removing the antibodies, the activity of the immunotoxins can be enhanced.
Inventors
- 👤 Joseph P. Balint, Jr.
- 👤 Sharon Cochran
- 👤 Frank R. Jones
- 👤 Harry W. Snyder
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 02:38
CPC Classifications
A; A61; A61M; A61M1/00; A61M1/36; A61M1/3679; A61M1/34; A61M1/3472; A61M1/3486; A61M1/3616
Claims Analysis
Total Claims: 28
Claim 1
Independent Claim
39 words
A method for inhibiting sensitivity in a vertebrate host undergoing therapeutic or diagnostic administration of exogenous macromolecules, said method comprising the extracorporeal removal from the patient of endogenous antibodies produced in response to the administration of the exogenous macromolecules.
Claim 2
Independent Claim
39 words
A method for inhibiting sensitivity in a vertebrate host undergoing therapeutic or diagnostic administration of exogenous macromolecules, said method comprising the extracorporeal removal from the patient of endogenous antibodies produced in response to the administration of the exogenous macromolecules.
Claim 3
Dependent Claim
31 words
A method as in claim 1, wherein the removal of the endogenous antibodies is effected by passage of patient plasma through an immunoadsorbent having immobilized receptor specific for the endogenous antibody.
Claim 4
Dependent Claim
14 words
A method as in claim 2, wherein the receptor is the exogenous macromolecule itself.
Claim 5
Dependent Claim
18 words
A method as in claim 2, wherein the immunoadsorbent comprises receptor covalently bound to a physiologically inert matrix.
Claim 6
Dependent Claim
13 words
A method as in claim 4, wherein the physiologically inert matrix is silica.
Claim 7
Dependent Claim
28 words
A method as in claim 1, wherein endogenous antibody levels are reduced to about background titer levels or below immediately prior to the administration of additional exogenous antibody.
Claim 8
Dependent Claim
50 words
In a method for administering to a vertebrate host multiple doses of exogenous antibodies at preselected intervals between successive doses, the improvement comprising inhibiting immune sensitivity to such exogenous antibodies by the extracorporeal removal from the patient of endogenous antibodies produced in response to the administration of the exogenous antibodies.
Claim 9
Dependent Claim
50 words
In a method for administering to a vertebrate host multiple doses of exogenous antibodies at preselected intervals between successive doses, the improvement comprising inhibiting immune sensitivity to such exogenous antibodies by the extracorporeal removal from the patient of endogenous antibodies produced in response to the administration of the exogenous antibodies.
Claim 10
Dependent Claim
23 words
A method as in claim 7, wherein the endogenous antibodies are removed immediately prior to administration of a dose of the exogenous antibodies.
Claim 11
Dependent Claim
20 words
A method as in claim 8, wherein the endogenous antibody levels are reduced to about background titer levels or below.
Claim 12
Dependent Claim
16 words
A method as in claim 7, wherein the exogenous antibodies are coupled to a cytotoxic agent.
Claim 13
Dependent Claim
31 words
A method as in claim 7, wherein the removal of the endogenous antibodies is effected by passage of patient plasma through an immunoadsorbent having immobilized receptor specific for the endogenous antibody.
Claim 14
Dependent Claim
14 words
A method as in claim 11, wherein the receptor is the exogenous antibody itself.
Claim 15
Dependent Claim
18 words
A method as in claim 11, wherein the immunoadsorbent comprises receptor covalently bound to a physiologically inert matrix.
Claim 16
Dependent Claim
13 words
A method as in claim 13, wherein the physiologically inert matrix is silica.
Claim 17
Independent Claim
79 words
A method for treating a vertebrate host with exogenous antibodies, said method comprising the following steps: (a) removing blood from a patient who has previously been injected with exogenous antibodies which have in response produced endogenous antibodies; (b) separating the removed blood into cellular components and plasma; (c) contacting the plasma with an immunoadsorbent specific for the endogenous antibodies; (d) reinfusing the cellular components and the treated plasma into the patient; and (e) administering exogenous antibodies to the patient.
Claim 18
Independent Claim
79 words
A method for treating a vertebrate host with exogenous antibodies, said method comprising the following steps: (a) removing blood from a patient who has previously been injected with exogenous antibodies which have in response produced endogenous antibodies; (b) separating the removed blood into cellular components and plasma; (c) contacting the plasma with an immunoadsorbent specific for the endogenous antibodies; (d) reinfusing the cellular components and the treated plasma into the patient; and (e) administering exogenous antibodies to the patient.
Claim 19
Dependent Claim
20 words
A method as in claim 15, wherein steps (a) through (d) are performed and completed immediately prior to step (e).
Claim 20
Dependent Claim
21 words
A method as in claim 15, wherein the exogenous antibodies are specific for a class of abnormal cells within the patient.
Claim 21
Dependent Claim
13 words
A method as in claim 17, wherein the abnormal cells are neoplastic cells.
Claim 22
Dependent Claim
21 words
A method as in claim 15, wherein the exogenous antibodies are specific for a class of normal cells within the patient.
Claim 23
Dependent Claim
23 words
A method as in claim 19, wherein the normal cells are being evaluated to determine the size and position of a particular tissue.
Claim 24
Dependent Claim
16 words
A method as in claim 19, wherein the normal cells are heart muscle and vascular tissue.
Claim 25
Dependent Claim
31 words
A method as in claim 15, wherein the removal of the endogenous antibodies is effected by passage of patient plasma through an immunoadsorbent having immobilized receptor specific for the endogenous antibody.
Claim 26
Dependent Claim
23 words
A method as in claim 15, wherein the immunoadsorbent comprises a receptor specific for the exogenous antibody coupled to a physiologically inert matrix.
Claim 27
Dependent Claim
14 words
A method as in claim 23, wherein the receptor is the exogenous antibody itself.
Claim 28
Dependent Claim
13 words
A method as in claim 23, wherein the physiologically inert matrix is silica.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-09-11 | 1993-03-13 | 1993-09-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-09-11 | 1997-03-13 | 1997-09-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-09-11 | 2001-03-13 | 2001-09-12 | $7700.00 | Window Closed / Lapsed |